ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.54
-0.09%
US Tech 100
19,220.00
-0.20%
S&P 500
5,464.62
-0.16%
US Dollar vs CAD
1.36995
0.00%
Bitcoin
64,419.69
0.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Cellectis Nom Eo 05 (ALCLS)

  7. Cellectis Nom Eo 05 (ALCLS) News

ALCLS

Cellectis Nom Eo 05 (ALCLS)

Cellectis Nom Eo 05
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALCLS
DateTimeSourceHeadlineSymbolCompany
06/20/20243:30PMGlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingEU:ALCLSCellectis Nom Eo 05
06/20/20243:30PMGlobeNewswire Inc.Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editorsEU:ALCLSCellectis Nom Eo 05
06/20/20243:30PMGlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingEU:ALCLSCellectis Nom Eo 05
06/12/20243:30PMGlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsEU:ALCLSCellectis Nom Eo 05
06/12/20243:30PMGlobeNewswire Inc.Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature CommunicationsEU:ALCLSCellectis Nom Eo 05
06/12/20243:30PMGlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsEU:ALCLSCellectis Nom Eo 05
06/05/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
06/05/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
06/04/20243:30PMGlobeNewswire Inc.Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguëEU:ALCLSCellectis Nom Eo 05
06/04/20243:30PMGlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaEU:ALCLSCellectis Nom Eo 05
05/29/20243:30PMGlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
05/29/20243:30PMGlobeNewswire Inc.L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024EU:ALCLSCellectis Nom Eo 05
05/29/20243:30PMGlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
05/28/20243:30PMGlobeNewswire Inc.Cellectis publie ses résultats financiers du premier trimestre 2024EU:ALCLSCellectis Nom Eo 05
05/28/20243:30PMGlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024EU:ALCLSCellectis Nom Eo 05
05/27/20243:30PMGlobeNewswire Inc.Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024EU:ALCLSCellectis Nom Eo 05
05/27/20243:30PMGlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
05/27/20243:30PMGlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
05/16/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
05/16/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
05/06/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
05/06/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis annonce la réalisation de l’investissement additionnel d’AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis nomme Arthur Stril directeur financier par intérimEU:ALCLSCellectis Nom Eo 05
04/29/20243:46PMGlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
04/29/20243:46PMGlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
 Showing the most relevant articles for your search:EU:ALCLS

Your Recent History

LATK
NAMEUSDT
Polkadomain Token
TG
A3K8PP
ING Groep
LSE
96DP
Investec Bnk 24
USOTC
ZPAS
Zoompass (CE)
USOTC
CPKOD
Akwaaba Mining (PK)
BOV
ITUBH350
ITUBH350 Ex:31,43
TG
A3KTNM
Repsol
TSXV
TNV.P
NASDAQ
TASK
TaskUs
NASDAQ
PESI
PermaFix Environmental S...
LSE
70YD
Govsrilanka 24s
BIT
Q00440
Leonteq Securities
COIN
GUSDTUST
Global USD Token
USOTC
IIJIY
Internet Initiative Japan (PK)
BIT
P11YP8
BNP PARIBAS ISSUANCE
EU
SGSWN
Euronext Social Goods an...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved